Skip to content

Study · Randomized controlled trial · n = 29 · 2025

3 results

Efficacy of Somapacitan in Treatment-Fatigue Adult Patients With Growth Hormone Deficiency Previously Treated With Once-Daily Growth Hormone Injections: A 24-Week Randomized Active-Controlled Trial.

Jensterle M, Herman R, Klinc A, Goričar K, Rakusa M, Janež A

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists17 Mar 2025Cited by 3 (Europe PMC)

PMID40107502 (opens in a new tab)DOI10.1016/j.eprac.2025.03.005 (opens in a new tab)PepBankPUB-40107502
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with GHD and injection fatigue, somapacitan improved treatment convenience more than daily GH.

    In plain wordsIn adults with GHD and injection fatigue, somapacitan improved convenience more than daily GH.

    Peptide
    Somapacitan
    Outcome
    IncreaseTreatment convenience
    Study

    n = 29

    Comparator
    Daily GH
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Estimated difference
    23.2 points
    somapacitan minus daily GH
    95% CI
    7.9 to 38.4 points
    P
    0.004

    Source sentences

    Summary
    The difference in change in Treatment Satisfaction Questionnaire for Medication-9 score for convenience was significant, in favor of somapacitan (estimated difference, somapacitan-daily GH [95% CI]:23.2 [7.9; 38.4] points, P = .004).
    1 context sentence
    Summary · context
    Twenty-nine adult patients with GHD, pretreated with daily GH for ≥5 years, who had reported treatment-related fatigue, were randomized to somapacitan or daily GH.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with GHD, somapacitan and daily GH did not differ in IGF-1, glucose, lipids, visceral adipose tissue, fat percentage, lean mass, or vascular changes.

    In plain wordsIn adults with GHD, somapacitan and daily GH showed similar changes in IGF-1, glucose, lipids, visceral fat, fat percentage, lean mass, and vascular measures.

    Peptide
    Somapacitan
    Outcome
    No significant changeMetabolic, body composition and vascular parameters
    Study

    n = 29

    Comparator
    Daily GH
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    No differences between treatment arms in estimated changes from baseline to study-end were observed for IGF-1 levels, glucose and lipid profile, visceral adipose tissue, fat mass (%), lean body mass, and vascular parameters.
    1 context sentence
    Summary · context
    Twenty-nine adult patients with GHD, pretreated with daily GH for ≥5 years, who had reported treatment-related fatigue, were randomized to somapacitan or daily GH.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with GHD, lumbar spine BMD change was lower with somapacitan than daily GH.

    In plain wordsIn adults with GHD, lumbar spine bone density change was lower with somapacitan than daily GH.

    Peptide
    Somapacitan
    Outcome
    DecreaseLumbar spine BMD
    Study

    n = 29

    Comparator
    Daily GH
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Estimated difference
    −0.036 gr/cm2
    somapacitan minus daily GH
    95% CI
    −0.064 to −0.009 gr/cm2
    P
    0.011

    Source sentences

    Summary
    There was significant difference in BMD of the lumbar spine (estimated difference, somapacitan-daily GH [95% CI] -0.036 (-0.064, -0.009) gr/cm2, P = .011).
    1 context sentence
    Summary · context
    Twenty-nine adult patients with GHD, pretreated with daily GH for ≥5 years, who had reported treatment-related fatigue, were randomized to somapacitan or daily GH.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.